PriceTargets.com logo

Genus - GNS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,850 As of 05/17/2024 01:00 AM ET
▼ -30 (-1.60%)

This chart shows the closing price for GNS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNS

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Genus in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 1,850.

This chart shows the closing price for GNS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Genus. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/16/2023Peel HuntReiterated RatingBuyGBX 4,500
4/12/2022Peel HuntReiterated RatingHoldGBX 4,500
12/7/2021Liberum CapitalReiterated RatingBuyGBX 5,740
11/24/2021Liberum CapitalLower TargetBuyGBX 6,000 ➝ GBX 5,740
11/3/2021Liberum CapitalReiterated RatingBuyGBX 6,000
9/9/2021Liberum CapitalReiterated RatingBuyGBX 5,630
6/29/2021CitigroupReiterated RatingHoldGBX 5,500
6/29/2021Numis SecuritiesReiterated RatingAddGBX 5,500
6/23/2021Liberum CapitalReiterated RatingBuyGBX 5,630
6/22/2021Peel HuntReiterated RatingBuyGBX 5,500
6/22/2021Peel HuntReiterated RatingBuyGBX 5,500
1/18/2021Liberum CapitalBoost TargetBuyGBX 4,490 ➝ GBX 4,760
6/30/2020Peel HuntReiterated RatingHold
6/18/2020Liberum CapitalBoost TargetBuyGBX 3,450 ➝ GBX 4,120
6/3/2020Peel HuntReiterated RatingHold
5/8/2020Peel HuntReiterated RatingHold
4/30/2020Peel HuntDowngradeHold
4/7/2020Peel HuntReiterated RatingBuy
4/1/2020HSBCBoost TargetBuyGBX 3,260 ➝ GBX 3,550
4/1/2020Peel HuntReiterated RatingBuy
3/23/2020Liberum CapitalReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/27/2020Liberum CapitalReiterated RatingBuy
2/24/2020Peel HuntReiterated RatingBuy
2/13/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/6/2020Peel HuntReiterated RatingBuy
12/11/2019Peel HuntReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/28/2019Liberum CapitalBoost TargetBuyGBX 2,800 ➝ GBX 3,450
11/20/2019Peel HuntReiterated RatingBuy
11/20/2019Liberum CapitalReiterated RatingBuy
11/15/2019Jefferies Financial GroupInitiated CoverageHoldGBX 3,272
11/14/2019Peel HuntReiterated RatingBuyGBX 3,200
11/14/2019Liberum CapitalReiterated RatingBuyGBX 2,800
11/13/2019HSBCBoost TargetBuyGBX 3,000 ➝ GBX 3,260
11/11/2019Peel HuntReiterated RatingBuyGBX 3,200
11/4/2019Peel HuntReiterated RatingBuy
10/21/2019Peel HuntReiterated RatingBuy
10/21/2019Liberum CapitalReiterated RatingBuy
10/7/2019Peel HuntReiterated RatingBuy
9/16/2019Peel HuntReiterated RatingBuy
9/11/2019Peel HuntReiterated RatingBuyGBX 3,200
9/10/2019Peel HuntReiterated RatingBuyGBX 3,200
9/6/2019Liberum CapitalReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
8/22/2019Peel HuntReiterated RatingBuyGBX 3,200
8/22/2019Peel HuntReiterated RatingBuyGBX 3,200
8/1/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/4/2019Peel HuntReiterated RatingBuy
5/29/2019Stifel NicolausInitiated CoverageHoldGBX 2,685
5/28/2019Peel HuntReiterated RatingBuy
(Data available from 5/18/2019 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Genus logo
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Read More

Today's Range

Now: GBX 1,850
Low: 1,842
High: 1,912

50 Day Range

MA: GBX 1,788.42
Low: 1,700
High: 1,898

52 Week Range

Now: GBX 1,850
Low: 1,478
High: 2,572

Volume

31,130 shs

Average Volume

97,732 shs

Market Capitalization

£1.22 billion

P/E Ratio

3,627.45

Dividend Yield

1.71%

Beta

0.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Genus?

The following Wall Street sell-side analysts have issued reports on Genus in the last year:
View the latest analyst ratings for GNS.

What is the current price target for Genus?

0 Wall Street analysts have set twelve-month price targets for Genus in the last year. has the lowest price target set, forecasting a price of £100,000 for Genus in the next year.
View the latest price targets for GNS.

What is the current consensus analyst rating for Genus?

Genus currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GNS.

What other companies compete with Genus?

Other companies that are similar to Genus include Oxford Nanopore Technologies, Ergomed, PureTech Health, Silence Therapeutics and Oxford Biomedica. Learn More about companies similar to Genus.

How do I contact Genus' investor relations team?

Genus' physical mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company's listed phone number is +44-1256-347100. The official website for Genus is www.genusplc.com. Learn More about contacing Genus investor relations.